← Back to Clinical Trials
Recruiting Phase 4 NCT06666556

NCT06666556 Bowel Preparation in Colonoscopy: Lactulose Vs Polyethyleneglycol, Randomized Double-blind Comparative Clinical Trial, Multicenter Study.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06666556
Status Recruiting
Phase Phase 4
Sponsor Hospital Civil de Guadalajara
Condition Colorectal Cancer Screening
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2024-07-20
Primary Completion 2025-07-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 79 Years
Study Type INTERVENTIONAL
Interventions
Bowel preparation before colonoscopyBowel preparation before colonoscopy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.

This trial targets 300 participants in total. It began in 2024-07-20 with a primary completion date of 2025-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial it is to bowel the instestinal preparation with lactulose vs poliethylenglicol as better agent to have a quality colonoscopy and demostrate that lactulose is most efective, has a good tolerance and the patient would have a better satisfaction, so the question is: wich is the eficancy of lactulose in comparision with thepoliethylenglycol in the intestinal preparation for the colonoscopy?

Eligibility Criteria

* Inclusion Criteria: * Patients with indication for colonoscopy in our coloproctology service * Both women and men * Patients within an age range of 18-79 years * Patients who agree having a colonoscopy and who sign the informed consent to participate in the protocol Exclusion Criteria: * Patients under 18 or over 80 years old * All patients that won´t like to participate in the protocol or won´t sign the informed consent * Pregnant women * Patients with a medical record of colonic resection, ostomy status, severe cardiopulmonary and renal diseases, major psychiatric disorders, therapeutic colonoscopy or any contraindications for colonoscopy * Non compliance with the colonic preparation regimen * Active bleeding during the procedure * Patients with a known diagnosis of colorectal cancer

Contact & Investigator

Central Contact

Roberto U M. C. Roberto Ulises Cruz Neri (Master in Science, Medical Sta, M. C

✉ robertocruzneri@gmail.com

📞 +52 3311946664

Frequently Asked Questions

Who can join the NCT06666556 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 79 Years, studying Colorectal Cancer Screening. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06666556 trial and what does that mean for participants?

Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.

Is NCT06666556 currently recruiting?

Yes, NCT06666556 is actively recruiting participants. Contact the research team at robertocruzneri@gmail.com for enrollment information.

Where is the NCT06666556 trial being conducted?

This trial is being conducted at Guadalajara, Mexico, Guadalajara, Mexico, México, Mexico.

Who is sponsoring the NCT06666556 clinical trial?

NCT06666556 is sponsored by Hospital Civil de Guadalajara. The trial plans to enroll 300 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology